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Abstract 
The most promising techniques for detecting minimal residual disease (MRD) in canine lymphoma 
are flow cytometry (FC) and polymerase chain reaction amplification of antigen receptor genes 
(PARR). However, the agreement between these methods has not been established. MRD was 
monitored by FC and PARR following treatment of dogs affected with diffuse large B-cell 
lymphoma (DLBCL), comparing results in lymph node (LN), peripheral blood (PB) and bone 
marrow (BM) samples. The prognostic impact of MRD on time to relapse (TTR) and lymphoma-
specific survival (LSS) was also assessed. 
Fourteen dogs with previously untreated DLBCL were enrolled into the study; 10 dogs eventually 
relapsed, while four dogs with undetectable MRD were still in remission at the end of the study. At 
diagnosis, the concordance rate between FC and PARR was 100%, 78.6%, and 64.3% for LN, PB 
and BM, respectively. At the end of treatment, the agreement rates were 35.7%, 50%, and 57.1% 
for LN, PB and BM, respectively. At least one of the follow-up samples from dogs experiencing 
relapse was PARR
+
; conversely, FC was not able to detect MRD in seven of the dogs that relapsed. 
PARR was more sensitive than FC in predicting TTR, whereas the combination of PARR and FC 
was more sensitive than either technique alone in predicting LSS using PB samples. The results 
suggest that immunological and molecular techniques should be used in combination when 
monitoring for MRD in canine DLBCL. 
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Introduction 
Development of better treatments for diffuse large B-cell lymphoma (DLBCL) in dogs has resulted 
in improvements in terms of prognosis (Garrett et al, 2002 and Simon et al, 2006). However, 
following chemotherapy, the continued presence of malignant cells, representing minimal residual 
disease (MRD), places dogs affected with DLBCL at risk of relapse and consequently treatment is 
rarely curative (Marconato et al., 2011). Therefore, challenges remain in terms of detecting and 
eradicating residual tumour cells completely, thereby improving outcome. Lymph node (LN), bone 
marrow (BM) and peripheral blood (PB) involvement in lymphoma has traditionally been detected 
by cytology and flow cytometry (FC) (Marconato et al, 2013 and Martini et al, 2013); however, if 
the burden of malignant cells is low, FC might not be sufficiently sensitive to detect some cases 
with MRD (Merli et al., 2010). 
In recent years, molecular techniques have been introduced for diagnostic purposes (Burnett et al., 
2003), for molecular staging at diagnosis (Lana et al, 2006 and Sato et al, 2013) or for monitoring 
during chemotherapy (Yamazaki et al, 2008 and Yamazaki et al, 2010; Sato et al, 2011 and Sato et 
al, 2013; Gentilini et al., 2013). Detection of MRD using PB samples, taken following treatment, 
can be used to judge treatment efficacy and to select dogs that might benefit from consolidation 
chemotherapy, despite complete remission (CR) as determined clinically (Yamazaki et al, 
2010 and Sato et al, 2011). While all these studies have analysed circulating neoplastic cells, only 
one study focused on residual disease in LN aspirates (Thilakaratne et al., 2010), finding no 
significant correlation between MRD detection in PB and LN. 
MRD can be determined in canine B-cell lymphoma by FC and polymerase chain reaction 
amplification of antigen receptor genes (PARR). The immunoglobulin heavy chain (IgH) genes 
represent the most useful molecular target for detecting B-cell clonality, since they rearrange during 
early lymphoid development and demonstrate extensive junctional diversity (Mitterbauer-
Hohendanner et al., 2004). The aims of the present study were to determine the presence of 
rearranged IgH genes in LN, BM and PB samples from dogs affected with DLBCL, following 
treatment, to compare this technique to FC. Moreover, the study was designed to assess whether 
LN, PB or BM were equivalent, as tissue sources to detect MRD and also to determine the 
prognostic impact of MRD, determined by FC and PARR, on time to relapse (TTR) and lymphoma-
specific survival (LSS). 
Material and methods 
Animals and inclusion criteria 
Client-owned dogs, with recently diagnosed, histologically confirmed DLBCL, were prospectively 
enrolled. To be eligible for recruitment, dogs were required to undergo complete staging 
(Marconato et al., 2013), including FC on LN, PB and BM aspirates and histopathological 
evaluation of the previously aspirated LN, which was surgically removed (further information in 
Appendix S1 in the online version at doi:10.1016/j.tvjl.2014.03.006: Supplementary data). Written, 
informed consent was obtained from all owners and the study conformed to Italian law on use of 
animals in research (D. Lgs. n. 116/92). 
Treatment and evaluation of treatment response 
All dogs were enrolled in a therapeutic trial and received dose-intense chemotherapy, consisting of 
L-asparaginase, vincristine, cyclophosphamide, doxorubicin, lomustine, and prednisone (details of 
the protocol in Appendix S1 in the online version at doi:10.1016/j.tvjl.2014.03.006: Supplementary 
data), with some of the dogs also receiving an autologous vaccine (Marconato et al., 2014). The 
response to treatment was classified as CR, partial remission (PR), stable disease, or progressive 
disease (PD), based on previously published criteria (Vail et al., 2010). Responses were required to 
last for at least 28 days. Relapse was defined as clinical reappearance and cytological evidence of 
lymphoma at any anatomical site, in dogs having experienced CR, whereas relapse for animals with 
PR was defined as progression of disease. Response was evaluated at each chemotherapy session by 
measurement of peripheral LN. 
End-staging was carried out at the end of chemotherapy (T1), and all clinical, radiological, 
ultrasonographic, or laboratory investigations that indicated abnormalities at pretreatment staging 
(T0) were repeated. BM and PB were sampled again in all cases. Fine-needle aspiration of any 
peripheral LN that had been enlarged at diagnosis was carried out; the same LN was then surgically 
removed (end-staging lymphadenectomy). 
Tissue samples 
At T0 and T1, samples were collected for analysis. Samples included LN tissue in formalin and 
RNAlater solution (Life Technologies), fine-needle aspirates of peripheral enlarged LN in RPMI 
1640 (Sigma–Aldrich), PB and BM samples in EDTA sample tubes and RNAlater solution. For 
histopathological examination, 3 μm sections of formalin-fixed and paraffin-embedded LN were 
stained with haematoxylin and eosin. To confirm the B-cell phenotype, a panel of four antibodies 
was used (Appendix S1 in the online version at doi:10.1016/j.tvjl.2014.03.006: Supplementary 
data). Samples were classified, based on the WHO classification (Valli et al., 2011). 
Flow cytometry 
FC was performed on LN aspirates, BM and PB at T0 and T1 within 24 h of sampling, to confirm 
B-cell neoplasia and assess the level of infiltration (Appendix S1 in the online version at 
doi:10.1016/j.tvjl.2014.03.006: Supplementary data). For LN samples, 5000 events, representing 
CD45
+
 cells, were analysed, with 10,000 CD45
+
 cells analysed for PB and BM. At T0, LN samples 
were considered diagnostic for DLBCL when at least 80% of the CD45
+
 cells were large (i.e. 
FSC > 400) and CD21+. At T1, LN MRD was considered positive, if at least 1% of large CD21+ 
cells were detected. If large CD21
+
 cells were not detected by FC, due to scarce cellularity, LN 
samples were considered negative for MRD. At T0 and T1, the extent of PB and BM infiltration 
with malignant cells was reported as the percentage of large CD21
+
 cells in the total population of 
CD45
+
 cells, and was considered positive if >1%. 
DNA extraction and PARR 
Genomic DNA was extracted from LN, PB and BM using the DNeasy Blood & Tissue Kit 
(Qiagen), according to the manufacturer's instructions. DNA concentrations were measured by the 
use of a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies) and Qubit fluorometer 
(Life Technologies). Detection of antigen receptor gene rearrangement was assessed by PCR 
amplification of the complementarity-determining region 3 (CDR3) of the IgH receptor genes, as 
previously described (Burnett et al., 2003) (further details in Appendix S1 in the online version at 
doi:10.1016/j.tvjl.2014.03.006: Supplementary data). Samples were considered positive, if one 
dominant and discrete band was present, indicative of the presence of a monoclonal population of 
B-cells; whereas samples were considered negative, if no bands, a diffuse smear or a laddering were 
observed. 
The sensitivity of the PCR assay to detect a clonal lymphoid population within a polyclonal cell 
population was evaluated by mixing a starting amount of 30 ng DNA from a monoclonal cell 
population, obtained from a dog at T0 (100% clonal cells), with different amounts of a mixture of 
genomic DNA from mononuclear cells, obtained from 10 healthy individuals. The limit of detection 
of the assay required at least 300 pg DNA from the monoclonal cell population, diluted in 29.7 ng 
of polyclonal DNA. 
Statistical analysis 
TTR was calculated for dogs in CR or PR from T1 to clinical relapse or progression, respectively. 
Dogs lost to follow-up, deceased for lymphoma-unrelated causes before PD, or those still in CR at 
the end of the study, were censored for TTR analysis. Time to progression (TTP) was measured as 
the interval between the start of treatment and PD. LSS was measured as the interval between the 
start of treatment and death from lymphoma (Vail et al., 2010). Dogs alive at the end of the study, 
lost to follow-up or deceased due to lymphoma-unrelated causes were censored for survival 
analysis. 
The Kaplan–Meier method was used to assess the influence of LN, PB and BM infiltration with 
malignant cells, identified by FC and/or PARR, on TTR and LSS and the univariate association 
between groups was tested using the log-rank test. Analyses were performed using the SPSS 
statistical package version 12.0.1. P-values < 0.05 were considered to be significant. 
Results 
Clinical characteristics and outcome 
Fourteen dogs with DLBCL were enrolled (clinical details in Appendix S1 in the online version at 
doi:10.1016/j.tvjl.2014.03.006: Supplementary data). Thirteen dogs achieved CR and the other 
achieved PR, within 1–2 days after having received L-asparaginase. Ten dogs eventually relapsed, 
while four dogs were still in CR at the end of the study. Overall, median TTP was 242 days (range, 
31–635 days). At data analysis closure, eight dogs had died and six were still alive. Of those that 
had died, six dogs succumbed to lymphoma, whereas two died for unrelated causes. Median LSS 
was 362 days (range, 199–636 days). 
MRD evaluation by histopathology 
At T0, centroblastic DLBCL was diagnosed in all 14 dogs (Fig. 1a, b). At T1, all dogs underwent 
end-staging lymphadenectomy, indicating that two dogs still had DLBCL, with LN of the remaining 
12 dogs showing a distorted architecture, thickening of the peripheral capsule, with a diffuse size 
and reduced number of germinal centres. A mixture of small, medium and large lymphocytes was 
present in the cortex, with loss of normal anatomical distribution, admixed with frequent apoptotic 
cells. The medulla was characterised by an increased number of plasma cells and histiocytes 
(Fig. 1c, d). Eight of these 12 dogs eventually relapsed. 
 
Fig. 1.  
(a) Haematoxylin and eosin (HE) staining and (b) immunohistochemistry for CD20 in 
diffuse large B-cell lymphoma (DLBCL), centroblastic type. (c) HE staining of a surgically 
removed lymph node after treatment (T1): distorted architecture with thickening of the 
capsule and reduction of germinal centres. (d) A mixture of small, medium and large 
lymphocytes is present admixed with frequent apoptotic cells. 
MRD evaluation by flow cytometry 
At T0, DLBCL was diagnosed in all cases by FC analysis of LN. Malignant cells were identified in 
PB in seven cases, with a median percentage of 10.7% (range, 2–42%). BM infiltration was 
identified by FC in nine cases, with a median percentage of 7.2% (range, 1.2–60.7%). Six dogs 
showed simultaneous infiltration of PB and BM, whereas four did not show evidence of infiltration 
in either sample. At T1, 10 dogs were classified as being negative for MRD in all samples analysed. 
At T1, two dogs had detectable MRD in LN, and in the remaining 12 samples, large CD21
+
 cells 
accounted for <1%; therefore were classified as negative for MRD. MRD was detected in PB from 
three dogs, two of which only had PB MRD, whereas the other also showed evidence of MRD in 
LN and BM, with the latter dog the only one of the study population to demonstrate MRD in BM at 
this time point. 
MRD evaluation by PARR 
At T0, the B-cell phenotype of the lymphoma was confirmed in all dogs by PARR, indicating the 
presence of clonality in IgH gene rearrangements in LN samples. In PB and BM, PARR
+
 results 
were found in 10 and 11 dogs, respectively. Ten dogs showed clonal IgH gene rearrangements in 
both PB and BM, whereas three dogs did not show any evidence for clonal rearrangements in either 
sample. At T1, PARR
+
 results were found in 11, 10 and 7 dogs from analysis of LN, PB and BM 
samples, respectively. Seven dogs were PARR
+
 in both PB and BM, while four dogs did not show 
evidence of clonal rearrangements in either sample. 
Concordance between FC and PARR for detection of MRD 
At T0, the concordance rate between FC and PARR was 100%, 78.6%, and 64.3% for LN, PB and 
BM, respectively. The highest concordance rate was obtained with LN samples, with all dogs 
showing PARR
+
/FC
+
 results, whereas the highest discordance was obtained with BM samples, with 
three dogs being PARR
+
/FC
−
. At T1, samples showed a lower level of consistency, with an 
agreement rate of 35.7%, 50%, and 57.1% for LN, PB and BM samples, respectively; mostly due to 
PARR
+
/FC
−
 results being obtained. In contrast, BM samples showed a higher level of agreement, 
with seven cases being PARR
−
/FC
−
 (Table 1). Overall, 11 dogs had detectable MRD in at least one 
sample at T1. In 3/11 dogs, both FC and PARR results were positive in at least one sample. In 8/11 
dogs, PARR was positive, while FC did not show any detectable malignant cells. In three dogs, 
MRD could not be detected at T1 by either method in any sample. 
Table 1.  
Agreement between flow cytometry (FC) and polymerase chain reaction amplification of 
antigen receptor genes (PARR) for lymph node (LN), peripheral blood (PB) and bone 
marrow (BM) at T0 and T1 (n = 14). 
Time point Sample PARR
+
/FC
+
 PARR
−
/FC
+
 PARR
+
/FC
−
 PARR
−
/FC
−
 
T0 
LN 14 0 0 0 
PB 7 0 3 4 
BM 7 1 4 2 
T1 
LN 2 0 9 3 
PB 3 0 7 4 
BM 1 0 6 7 
MRD and clinical outcome 
In total, 10 dogs relapsed, either during treatment (n = 2) or afterwards (n = 8). Nine of these dogs 
showed PARR
+
 results in at least one of the samples assessed (Table 2). Conversely, FC was not 
able to detect MRD in seven of the 10 dogs that relapsed and malignant cells were detected by 
histopathology in only 2/10 dogs that relapsed. Of the four dogs in CR, both methods gave negative 
results in all samples for two dogs that had not relapsed, 636 and 602 days from T0, and 436 and 
420 days from T1, respectively. The third dog in CR, but with LN PARR
+
/FC
+
 results, died 69 days 
after T1 for lymphoma-unrelated causes. The LN sample from the fourth dog in CR was 
PARR
+
/FC
−
, who also died from lymphoma-unrelated causes, 342 days after T0 and 154 days from 
T1. 
Table 2.  
Clinical outcome and molecular profiling of 14 dogs with diffuse large B-cell lymphoma 
(DLBCL). 
Dog Histopathology at T1 FC results at T1 PARR results at T1 TTR (days) LLS (days) 
1 Follicular atrophy LN
−
, PB
+
, BM
−
 LN
+
, PB
+
, BM
+
 30 237 
2 Follicular atrophy LN
−
, PB
+
, BM
−
 LN
+
, PB
+
, BM
+
 69 530 
3 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
-
, PB
-
, BM
-
 436
a
 636
a
 
4 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
-
, PB
-
, BM
-
 420
a
 602
a
 
5 Follicular atrophy LN
+
, PB
+
, BM
+
 LN
+
, PB
+
, BM
+
 8 257 
6 DLBCL LN
−
, PB
-
, BM
−
 LN
+
, PB
+
, BM
+
 0 214 
7 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
+
, PB
+
, BM
+
 63 569
a
 
8 DLBCL LN
−
, PB
-
, BM
−
 LN
+
, PB
+
, BM
-
 0 199 
9 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
+
, PB
-
, BM
-
 154
a
 342 
10 Follicular atrophy LN
+
, PB
-
, BM
−
 LN
+
, PB
+
, BM
+
 69
a
 237 
11 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
+
, PB
+
, BM
-
 34 272 
12 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
-
, PB
-
, BM
-
 153 365
a
 
13 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
+
, PB
+
, BM
-
 85 364
a
 
14 Follicular atrophy LN
−
, PB
-
, BM
−
 LN
+
, PB
+
, BM
+
 63 383
a
 
TTR, time to relapse; LSS, lymphoma-specific survival; LN, lymph node; PB, peripheral 
blood; BM, bone marrow. 
aOngoing. 
Correlation between MRD and TTR 
PARR was more sensitive than FC in predicting TTR (Table 3). When considering MRD, based on 
analysis of LN samples at T1, median TTR was 63 days for dogs with PARR
+
 results, and was not 
reached for dogs with PARR
−
 results (P = 0.0492). Conversely, the difference in TTR comparing 
FC
+
 and FC
−
 dogs was not statistically significant. Dogs that were PARR
+
/FC
−
 for LN samples had 
a significantly shorter median TTR, compared with dogs demonstrating PARR
−
/FC
−
 results 
(P = 0.0448; Fig. 2a). All other combinations were not statistically significant. 
Table 3.  
Time to relapse (TTR) and lymphoma-specific survival (LSS) according to FC and PARR 
results. 
Endpoint Sample Technique 
Median 
(days) 
Mean 
(days) 
95% CI 
Log rank 
test 
P-
value 
TTR 
LN 
PARR
+
 63 66 26–106 
3.87 0.0492 
PARR
−
 NA 342 
191–
493 
FC
+
 23 46 14–78 
0.02 NS 
FC
−
 69 152 56–247 
PB 
PARR
+
 34 46 26–66 
8.54 0.0035 
PARR
−
 NA 365 
245–
485 
FC
+
 30 41 13–69 3.44 NS 
Endpoint Sample Technique 
Median 
(days) 
Mean 
(days) 
95% CI 
Log rank 
test 
P-
value 
FC
−
 85 181 70–292 
BM 
PARR
+
 63 48 26–71 
3.89 0.0487 
PARR
−
 153 226 87–364 
FC
+
 23 23 23–23 
3.01 NS 
FC
−
 76 161 64–258 
LSS 
LN 
PARR
+
 530 400 
330–
497 2.75 NS 
PARR
−
 NA 534 NA 
FC
+
 257 257 
257–
257 
0.4 NS 
FC
−
 530 483 
377–
589 
PB 
PARR
+
 272 383 
281–
485 3.75 NS 
PARR
−
 NA 486 NA 
FC
+
 257 341 
156–
527 
3.10 NS 
FC
−
 NA 521 
410–
632 
BM 
PARR
+
 530 405 
282–
528 
1.03 NS 
PARR
−
 NA 522 
387–
656 
FC
+
 257 257 
257–
257 
1.47 NS 
FC
−
 NA 490 
388–
592 
CI, confidence interval; NA, not applicable; NS, not significant. 
 
Fig. 2.  
Kaplan–Meier curve of time to relapse (TTR) for dogs with PARR−/FC−, PARR+/FC− and 
PARR
+
/FC
+
 results in (a) lymph node, (b) peripheral blood and (c) bone marrow. Kaplan–
Meier curve of lymphoma-specific survival (LSS) for dogs with PARR
−
/FC
−
, PARR
+
/FC
−
 
and PARR
+
/FC
+
 results in (d) lymph node, (e) peripheral blood and (f) bone 
marrow. + censored cases. 
When evaluating PB samples, median TTR was 34 days for dogs with PARR
+
 results, and was not 
reached for dogs with PARR
−
 results (P = 0.0035). The difference between FC+ and FC− samples 
was not statistically significant. PARR
−
/FC
−
 PB samples were associated with a longer TTR, 
compared with those that were PARR
+
/FC
+
 (P = 0.001) or PARR+/FC− (P = 0.0058; Fig. 2b). 
Dogs with PARR
+
 results for BM samples had a significantly shorter TTR, compared with dogs 
demonstrating PARR
−
 results (63 and 153 days, respectively; P = 0.048). The difference between 
FC
+
 and FC
−
 dogs was not statistically significant. None of the FC/PARR combinations were 
statistically significant (Fig. 2c). 
Correlation between MRD and LSS 
When considering MRD, based on analysis of LN, PB or BM at T1, there was no significant 
difference in LSS between PARR
+
 and PARR
−
, or between FC
+
 and FC
−
 samples (Fig. 2). 
Similarly, none of the FC/PARR combinations were statistically significant for LN or BM. For PB 
samples, a PARR
−
/FC
−
 result was associated with a longer LSS when compared with PARR
+
/FC
+
 
results (784 and 257 days, respectively; P = 0.0218; Fig. 2e) and the combination of PARR and FC 
was more sensitive than PARR or FC alone in predicting LSS (Table 3). 
Discussion 
In the present study, we investigated immunological (FC) and molecular (PARR) methods for 
detection of MRD in samples from 14 dogs affected with DLBCL. Each of these techniques has its 
own relative advantages, with selection largely dependent upon the expertise and facilities 
available, and on the purpose for which the method is being used. Advantages of FC include wide 
applicability, relatively quick results, low cost, capacity to sort residual lymphoma cells, and ability 
to distinguish between viable and non-viable cells. Advantages of PARR include easily 
interpretable results and potential for high sensitivity (Gaipa et al., 2012). 
The first aim of the study was to compare results obtained either by FC or PARR using the same 
samples. Overall, our data showed a moderate level of agreement, with results obtained in samples 
taken at T0, when the tumour burden was relatively high, showing a higher level of agreement, 
compared with samples taken during follow-up, after initiating treatment. Thus, with decreasing 
tumour burden in the animal, the sensitivity of FC became more critical, compared with PARR. 
At T0, there was full agreement between the two assays when analysing LN samples, whereas the 
greatest degree of discrepancy was found with BM. Several factors might have influenced this 
result. Firstly, two different BM aspirates were used for MRD detection by FC or PARR, and it has 
been demonstrated that the cellularity in a second BM aspiration, taken through the same needle, is 
likely to be lower, because of haemodilution (Lobetti-Bodoni et al., 2013). Secondly, the limited 
antibody panel available for canine samples may not allow optimal detection of malignant cells, 
thus impacting on the sensitivity of FC. At a threshold value of 1%, large B-cells in PB and BM, the 
concordance rate between FC and PARR was quite low. It is likely that MRD levels in these cases 
were <1% and, thus, below the limit of detection for FC. 
At T1, the concordance rate for BM and PB was similar to T0, while 9/14 LN samples showed 
discordant results. Interestingly, in nine dogs, LN analysis by PARR showed evidence of clonality, 
whereas FC failed to detect MRD. One explanation for this is the possibility of low level infiltration 
of neoplastic cells in the LN, which is detectable by PARR, but below the limit of detection by FC. 
Furthermore, in the present study, PARR was performed on tissue samples collected in RNAlater, 
whereas FC was performed on cell suspensions, collected by fine-needle aspiration, which might 
not necessarily be representative of the neoplastic infiltration. Alternatively, a variable proportion of 
neoplastic cells could have undergone apoptosis and would therefore have been excluded from the 
FC analysis (Gribben et al., 1992), but still likely detectable by PARR. Based on our results, LN 
molecular staging increased the diagnostic value of histopathological and flow-cytometric staging. 
Some of the dogs included in the study had received an autologous vaccine, which might interfere 
with detection of MRD. In a previously published paper, MRD could be detected, despite 
administration of chemo-immunotherapy, suggesting that the autologous vaccine did not impede 
detection of residual neoplastic cells (Marconato et al., 2014). 
In humans suffering from lymphoma, monitoring of MRD is currently used for therapeutic 
stratification and as a measure of outcome in clinical trials (Mitterbauer-Hohendanner et al, 2004, 
Yang et al, 2005 and Pott et al, 2013). We investigated whether MRD, determined by FC and/or 
PARR following treatment, had any prognostic impact on TTR and LSS. Although dose-intense 
chemotherapy leads to CR in the majority of dogs, most will relapse, and frequently die (Garrett et 
al, 2002, Simon et al, 2006 and Marconato et al, 2011). It is anticipated that monitoring for MRD 
might be used as a prognostic indicator, identifying those dogs with a high probability of relapse, so 
that more intense treatment can be initiated, and dogs with a lower probability of relapse can 
receive more conservative management, to reduce the risk of adverse effects of anti-cancer therapy. 
We found significant differences in TTR, when evaluating the two different methods (FC and 
PARR) and the three different samples (LN, PB and BM). The PARR assay was a better predictor 
than FC, when considering all analyses. There was no difference in TTR between dogs with FC-
detectable and undetectable MRD, regardless of the sample type. Thus, FC is likely to have a poor 
negative predictive value, with PARR representing a more sensitive method for predicting relapse. 
When used in combination on PB samples, PARR
+
/FC
+
 cases had shorter TTR when compared 
with PARR
−
/FC
−
 or PARR
+
/FC
−
 cases. 
It is noteworthy that only those dogs with PARR
−
/FC
−
 results in all three samples remained in CR. 
In contrast, dogs with PARR
+
/FC
−
 results eventually relapsed. Also, the absence of detectable MRD 
in PB and BM by PARR was not sufficient for predicting long-term remission. In terms of LSS, 
only the absence of MRD by both FC and PARR in PB correlated with a longer survival. However, 
these data need to be interpreted cautiously, as they could have been influenced by subjective client 
bias regarding end-of-life decisions. 
Conclusions 
FC and PARR provide interpretable data on MRD in DLBCL that can be applied for risk 
assignment. The use of PARR should offset the possibility of false-negative FC results in MRD 
evaluation. Indeed, if FC does not demonstrate clear evidence of residual disease, this does not 
imply MRD negativity, and PARR may be required. However, one potential limitation of routine of 
use of PARR for monitoring of MRD is that the technique is relatively labour-intensive and time-
consuming. On the other hand, if neoplastic cells have been identified by FC, this is suggestive of 
MRD and PARR is not necessary. When considering all analyses, LN seems to represent the best 
tissue source to detect MRD by PARR. 
As the number of dogs in the current study is relatively small and the follow-up short, conclusions 
about the clinical application of our research findings await confirmation. Further studies are 
needed, using FC and PARR, to monitor for MRD, to determine the prognostic value of these 
methods and their ability to segregate animals into risk categories. It remains to be shown whether 
earlier detection of an impending relapse, using PARR, is clinically advantageous. 
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